Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Gears Up For Phase III Trial For Biosimilar Of Roche’s Rituxan

This article was originally published in PharmAsia News

Executive Summary

Korea’s Celltrion said it is on path to a new Phase III trial design of a biosimilar of Roche’s Rituxan after presenting positive Phase I trial data in San Diego in late October.

You may also be interested in...



Which Biopharmas Are Best Positioned For Five-Year Growth?

Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.

Pfizer Hones Biosimilars Approach For Individual Countries

The company has biosimilars of Rituxan, Herceptin and Remicade in clinical trials and a biosimilar to Humira is about to enter Phase I; Pfizer is pursuing the biosimilar pathway for all of its candidates.

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082958

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel